These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37458596)

  • 21. [Expression pattern of the histone lysine demethylase family and its potential role in bladder cancer: a multi-omics analysis].
    Fu X; Yu G; Guo Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2022 Dec; 42(12):1822-1831. PubMed ID: 36651250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanics and dynamic simulations of well-known Kabuki syndrome-associated KDM6A variants reveal putative mechanisms of dysfunction.
    Chi YI; Stodola TJ; De Assuncao TM; Leverence EN; Tripathi S; Dsouza NR; Mathison AJ; Basel DG; Volkman BF; Smith BC; Lomberk G; Zimmermann MT; Urrutia R
    Orphanet J Rare Dis; 2021 Feb; 16(1):66. PubMed ID: 33546721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
    Revia S; Seretny A; Wendler L; Banito A; Eckert C; Breuer K; Mayakonda A; Lutsik P; Evert M; Ribback S; Gallage S; Chikh Bakri I; Breuhahn K; Schirmacher P; Heinrich S; Gaida MM; Heikenwälder M; Calvisi DF; Plass C; Lowe SW; Tschaharganeh DF
    Gut; 2022 Aug; 71(8):1613-1628. PubMed ID: 34509979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition.
    Boila LD; Ghosh S; Bandyopadhyay SK; Jin L; Murison A; Zeng AGX; Shaikh W; Bhowmik S; Muddineni SSNA; Biswas M; Sinha S; Chatterjee SS; Mbong N; Gan OI; Bose A; Chakraborty S; Arruda A; Kennedy JA; Mitchell A; Lechman ER; Banerjee D; Milyavsky M; Minden MD; Dick JE; Sengupta A
    Leukemia; 2023 Apr; 37(4):751-764. PubMed ID: 36720973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of KDM6A confers drug resistance in acute myeloid leukemia.
    Stief SM; Hanneforth AL; Weser S; Mattes R; Carlet M; Liu WH; Bartoschek MD; Domínguez Moreno H; Oettle M; Kempf J; Vick B; Ksienzyk B; Tizazu B; Rothenberg-Thurley M; Quentmeier H; Hiddemann W; Vosberg S; Greif PA; Metzeler KH; Schotta G; Bultmann S; Jeremias I; Leonhardt H; Spiekermann K
    Leukemia; 2020 Jan; 34(1):50-62. PubMed ID: 31201358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
    Watanabe S; Shimada S; Akiyama Y; Ishikawa Y; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Yamaoka S; Tanabe M; Tanaka S
    Int J Cancer; 2019 Jul; 145(1):192-205. PubMed ID: 30556125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic potential of inhibiting histone 3 lysine 27 demethylases: a review of the literature.
    Abu-Hanna J; Patel JA; Anastasakis E; Cohen R; Clapp LH; Loizidou M; Eddama MMR
    Clin Epigenetics; 2022 Aug; 14(1):98. PubMed ID: 35915507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone demethylase UTX/KDM6A enhances tumor immune cell recruitment, promotes differentiation and suppresses medulloblastoma.
    Yi J; Shi X; Xuan Z; Wu J
    Cancer Lett; 2021 Feb; 499():188-200. PubMed ID: 33253789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Re: Loss of Tumor Suppressor KDM6A Amplifies PRC2-Regulated Transcriptional Repression in Bladder Cancer and Can be Targeted through Inhibition of EZH2.
    Atala A
    J Urol; 2017 Nov; 198(5):984-985. PubMed ID: 29059780
    [No Abstract]   [Full Text] [Related]  

  • 30. Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells.
    Terashima M; Ishimura A; Wanna-Udom S; Suzuki T
    Biochem Biophys Res Commun; 2017 Sep; 490(4):1407-1413. PubMed ID: 28698146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutually exclusive mutation profiles define functionally related genes in muscle invasive bladder cancer.
    Sangster AG; Gooding RJ; Garven A; Ghaedi H; Berman DM; Davey SK
    PLoS One; 2022; 17(1):e0259992. PubMed ID: 35073341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3.
    Leng X; Wang J; An N; Wang X; Sun Y; Chen Z
    Oncogene; 2020 Oct; 39(41):6468-6479. PubMed ID: 32879445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of coding sequence, mRNA expression and three insertions/deletions (indels) of KDM6A gene in male pig.
    Cui Y; Chen R; Lv X; Pan C
    Theriogenology; 2019 Jul; 133():10-21. PubMed ID: 31051389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.
    Chen X; Yang Z; Feng J; Duan T; Pan T; Yan L; Jin T; Xiang Y; Zhang M; Chen P; Wang W; Zhang R; Chen B; Zhao L; Xie T; Sui X
    Cancer Med; 2021 Jan; 10(1):317-324. PubMed ID: 33174323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Catalytic domain-dependent and -independent transcriptional activities of the tumour suppressor histone H3K27 demethylase UTX/KDM6A in specific cancer types.
    Sun W; Lee KL; Poellinger L; Masai H; Kato H
    Epigenetics; 2023 Dec; 18(1):2222245. PubMed ID: 37300822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of lysine-specific demethylase 6A (KDM6A) in tumorigenesis and its therapeutic potentials in cancer therapy.
    Chen LJ; Xu XY; Zhong XD; Liu YJ; Zhu MH; Tao F; Li CY; She QS; Yang GJ; Chen J
    Bioorg Chem; 2023 Apr; 133():106409. PubMed ID: 36753963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of potential therapeutic targets in urothelial bladder carcinoma of Chinese population by targeted next-generation sequencing.
    Wang T; Liu Z; Wang X; Bai P; Sun A; Shao Z; Luo R; Wu Z; Zhang K; Li W; Xiao W; Duan B; Wang Y; Chen B; Xing J
    Cancer Biol Ther; 2020 Aug; 21(8):709-716. PubMed ID: 32449441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel KDM6A (UTX) mutations and a clinical and molecular review of the X-linked Kabuki syndrome (KS2).
    Banka S; Lederer D; Benoit V; Jenkins E; Howard E; Bunstone S; Kerr B; McKee S; Lloyd IC; Shears D; Stewart H; White SM; Savarirayan R; Mancini GM; Beysen D; Cohn RD; Grisart B; Maystadt I; Donnai D
    Clin Genet; 2015 Mar; 87(3):252-8. PubMed ID: 24527667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diverse ways to be specific: a novel Zn-binding domain confers substrate specificity to UTX/KDM6A histone H3 Lys 27 demethylase.
    Kim E; Song JJ
    Genes Dev; 2011 Nov; 25(21):2223-6. PubMed ID: 22056667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. UTX Mutations in Human Cancer.
    Wang L; Shilatifard A
    Cancer Cell; 2019 Feb; 35(2):168-176. PubMed ID: 30753822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.